December 17

3 reasons why credit unions should offer contactless cards

first_imgThe U.S. payments industry is experiencing a turning point in the adoption of contactless EMV. According to Mastercard, nearly 800,000 unique merchant locations were contactless-enabled in 2017. By the end of 2019, the company expects 65 percent of U.S. merchants will accept contactless payment methods. As large issuers move to offer contactless cards, why should credit unions also consider making the switch? The answer is as easy as one, two, three. ConvenienceCardholders are constantly looking for a more convenient way to process their transactions. While conditioned to stand in line, punch in a PIN or wait to sign for their transactions, currently paying with a chip-enabled plastic amounts to a seconds-long transaction. In comparison, using contactless “tap and go” technology will reduce that time to one second, providing an expedited and convenient experience at the point of sale.Adoption of this payment method is subsequently expected to impact the usage of mobile wallets, but not until consumers become accustomed to the “tap and go” payment experience that contactless cards will deliver. Eventually, consumers will have access to more payment options at the click of a finger and the ability to pay with a simple tap, making the purchasing experience for all consumers at any point-of-sale location simple and seamless – whether they use a card, mobile device, wearable or other payment object. PopularityVisa estimates that 100 million contactless cards will be in circulation in the U.S. by the close of 2019 and seven out of 10 cards will be contactless across the world by 2021. As such, more and more merchants are turning on the NFC (near field communication) functionality at the point of sale, and large issuers are finalizing their contactless cards distribution plans. Recent announcements from Target, Chase and Citi are touting their readiness for contactless payments, while merchants like Panera, Walgreens and Whole Foods, among others, are already accepting this method of payment in locations across the country. Visa and Mastercard are working with multiple municipal transit authorities, including Chicago, New York and Atlanta, to accept phone apps and contactless cards for entrance into their mass transit systems. Once contactless has been adopted by these mass transit systems and used by millions of Americans on a daily basis, adoption of other contactless methods – like payment with a contactless-enabled card – will increase and expand quickly.This provides an opportunity for credit unions’ cards to gain that coveted top-of-wallet spot due to the ease and convenience of contactless. More TransactionsDoes any credit union want to see a loss of transactions by not being ready with contactless card programs? Absolutely not. Credit unions must keep pace with their competition or risk the loss of transactions, which could ultimately result in loss of interest and interchange income – two vital components of any card program. Credit unions should evaluate the growth opportunity, costs and their member base to determine if contactless cards are the right move and, if so, determine when and how to get contactless cards in the hands of their members. It will also be important to build education and awareness for members ahead of issuance, whether that be through mass reissue or when new cards are issued to members due to loss, fraudulent activity and the like.Consumer demand for the latest technology will grow as contactless becomes more widespread, which is why credit unions should get ahead of mass adoption now in order to keep their solutions and offerings as current and competitive as possible. 14SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr,Dr. Art Harper Dr. Arthur (Art) Harper is part of the EMV team at PSCU, the company that is certified and was the first to issue credit, debit and prepaid EMV cards in … Web: www.pscu.com Detailslast_img read more

November 20

Rick Santorum pitched the government on a tiny, one-person company run by a political backer

first_imgSantorum later invested his own money in Zurlo’s struggling company, and it was Santorum who pitched the company to the FDA and the Department of Health and Human Services (HHS). Santorum isn’t shy about acknowledging that he’ll be getting some coin, either, if government dollars happen to jump-start this tiny, unknown company headed by one of his prior funders.All of that is beginning to sound a bit familiar at this point. Prominent conservative TV voice pitches the administration on a new, unproven medical technology mirroring one of Donald Trump’s own most talked-about potential miracle cures. Though even a cursory look at the company shows that it barely exists, and though government scientists are themselves dubious as to its value, the government is eager to latch on. It turns out the conservative who pushed the product is himself an investor, and could profit enormously if the contracts go through.It’s not the My Pillow guy trying to sell Trump new anti-coronavirus nutritional supplements, mind you, but it’s still a bit sketchy looking, eh?- Advertisement – In this case, although the AP reports that HHS scientists were not particularly impressed with the company’s pitch, the government is “latching on” with $750,000 in funding for a proof of concept, with tens of millions for building a company facility from scratch if it works out. If it does, CNN talking head Santorum will see his sunk investment explode in value; if it doesn’t, the government will have devoted another nontrivial bit of COVID-19 management and brainpower to a miracle that wasn’t.Still, as far as future scandals go, this one is comfortably familiar. We can take solace in the fact that even if this does turn out to be another case of government money being handed out solely because an administration ally is pushing the effort, it’s a bit of old school American institutional corruption, not one of Trump’s own crazy new inventions like “extort the president of Ukraine” or “invite Russian assets to give you a private sales pitch on how to damage your election opponent.”Any other year, Santorum would be getting a hard side-eye on this one, but now? Right now the swamp is so full-up you can barely see his nose peeking up out of the water. The actions of Trump’s cabinet alone will take the combined attention of every last inspector general and federal investigator during any upcoming Biden term; they won’t have a moment to even think about such embarrassingly normal political sketchiness.- Advertisement – The blood plasma company in line to get $65 million, Plasma Technologies, does not have any physical facilities. It is registered at the South Carolina home address of “connected” Republican donor Eugene Zurlo, a man who has been attempting to sell his technology for some time with no success. It looks like it has never produced plasma.And, most curiously, the one-person shadow company appears to have gained the attention of the government solely due to the connections of its most prominent outside investor, ex-senator turned CNN pundit Rick Santorum. Santorum, it turns out, was one of the prime beneficiaries of Zurlo’s Republican donations, and Zurlo previously “entertained Santorum and his family” at his now-sold South Carolina mansion, reports AP.- Advertisement –center_img – Advertisement –last_img read more

September 24

Batesville man sentenced for robbing gas station

first_imgVERSAILLES, Ind. — The Batesville man who pleaded guilty to robbing the Huck’s gas station in February of 2015 has been sentenced.Derek Douglas recently pleaded guilty to Armed Robbery.The original charge of theft was dismissed.Douglas has been sentenced to 10 years in prison with three years probation.He was able to get away from the scene on foot but was later found after a K9 officer tracked him to an apartment building within a few blocks of the gas station.last_img

January 18

Hawks acquire point guard Trae Young in swap of top-5 picks

first_imgOklahoma’s Trae Young, right, poses with NBA Commissioner Adam Silver after he was picked fifth overall by the Dallas Mavericks during the NBA basketball draft in New York, Thursday, June 21, 2018. (AP Photo/Kevin Hagen)ATLANTA — The Atlanta Hawks have added a new floor leader to their rebuilding effort by acquiring point guard Trae Young from the Dallas Mavericks in an exchange of NBA draft picks with the Dallas Mavericks.The Hawks drafted guard Luka Doncic of Slovenia with the No. 3 overall pick and then traded rights to Doncic to Dallas for rights to Young, the No. 5 overall pick, and a 2019 first-round pick. The trade was announced at the draft.ADVERTISEMENT Schroder said in a recent interview in his native Germany he would like to be traded. Carpio hits red carpet treatment for China Coast Guard PLAY LIST 02:14Carpio hits red carpet treatment for China Coast Guard02:56NCRPO pledges to donate P3.5 million to victims of Taal eruption00:56Heavy rain brings some relief in Australia02:37Calm moments allow Taal folks some respite03:23Negosyo sa Tagaytay City, bagsak sa pag-aalboroto ng Bulkang Taal01:13Christian Standhardinger wins PBA Best Player award Volcano watch: Island fissures steaming, lake water receding Sports Related Videospowered by AdSparcRead Next The Hawks have four picks in the top 34, including three in the first round. The Hawks also have No. 19 and No. 30 picks in the first round and the No. 34 selection in the second round.The trade was not a major surprise. With so many draft picks, Hawks general manager Travis Schlenk said last week he was entertaining numerous trade offers.The Hawks, who finished last in the Eastern Conference last season, will continue their rebuilding effort with Young and first-year coach Lloyd Pierce.Mike Budenholzer was hired as Milwaukee’s new coach after reaching a mutual agreement to leave the Hawks.Young joins an Atlanta roster which returns few set starters. Forward-center John Collins showed promise as a rookie last season, and forward Taurean Prince is another young piece of the rebuilding effort. Veterans Kent Bazemore and Dwayne Dedmon are under contract for next season.ADVERTISEMENT Bicol riders extend help to Taal evacuees Jury of 7 men, 5 women selected for Harvey Weinstein rape trial NBA Draft: Cavs select Bama’s Sexton to help convince LeBron to stay Christopher Tolkien, son of Lord of the Rings author, dies aged 95 Young led the nation with his averages of 27.4 points and 8.7 assists for Oklahoma. The 6-foot-2 Young scored at least 40 points in four games and tied a Division I record by recording 22 assists in a game.The Hawks’ decision to acquire Young likely means veteran guard Dennis Schroder’s future with the team could be short-lived.FEATURED STORIESSPORTSGinebra beats Meralco again to capture PBA Governors’ Cup titleSPORTSAfter winning title, time for LA Tenorio to give back to Batangas folkSPORTSTim Cone, Ginebra set their sights on elusive All-Filipino crownThis is not the first time the Hawks have quickly traded the No. 3 overall pick. In 2001, the Hawks made Pau Gasol the No. 3 overall pick and then traded his draft rights to the Memphis Grizzlies for Shareef Abdur-Rahim.Doncic was Atlanta’s highest draft pick since 2007, when center Al Horford was the No. 3 pick.center_img LATEST STORIES Cloudy skies over Luzon due to amihan Don’t miss out on the latest news and information. Taal victims get help from Kalayaan town Jiro Manio arrested for stabbing man in Marikina MOST READ In fight vs corruption, Duterte now points to Ayala, MVP companies as ‘big fish’ Lights inside SMX hall flicker as Duterte rants vs Ayala, Pangilinan anew View commentslast_img read more

December 21

Convoy Community Park to offically open today

first_imgThe Convoy Community Park is set to have its official opening today at 11am and it is being greatly received by the community. Funding for the park was sanctioned following an application to the council through the Town and Village Renewal Scheme.Cllr Liam Doherty, who is on the Convoy Environmental Committee, was among the Environmental Committee members Liam Mailey, Caroline Mailey, John Toner, Brian Duffy and Josephine Cowan gave Sinn Fein TD Pearse Doherty a tour of the beautiful newly opened community park. Commenting on the park, Councillor Doherty said he was delighted with how it turned out for the local community.He said: “I am so happy with our beautiful park here in Convoy, it gives me great pride to see such a wonderful development here in my home town and I know the local people who share my pride will get great enjoyment out of the park.“I would like to thank Donegal County Council for funding this project, all councillors who supported it and everyone involved in the development of the park.”Convoy Community Park to offically open today was last modified: May 18th, 2019 by Shaun KeenanShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:convoylast_img read more

December 20

Will Smith signs with Atlanta Braves, Madison Bumgarner expected to reject Giants’ qualifying offer

first_imgSAN FRANCISCO — The Atlanta Braves are expected to be one of the teams that pursues former Giants ace Madison Bumgarner in free agency this offseason.On Thursday, the Braves announced they signed another high-profile left-hander who was a big part of the 2019 Giants’ pitching staff.Atlanta agreed to terms with former Giants closer Will Smith on a three-year deal worth $39 million that includes a club option of $13 million for the 2023 season. The deal was completed minutes before MLB’s …last_img read more

December 19

TB vaccine in SA clinical trial

first_imgA doctor examining chest X-rays at aTB clinic in Cape Town. (Image: USDepartment of State official blog) Educational poster for TB, publishedby TB Care in Cape Town.(Image: World Lung Foundation) A rural health clinic, where patients aretreated for, among others, TB. (Image:Damien Schumann, World Lung Foundation)Janine ErasmusSouth Africa is the setting for a phase II clinical trial of an advanced new tuberculosis vaccine. The trial is to be conducted by the non-profit Aeras Global TB Vaccine Foundation, which is supported by the Bill and Melinda Gates Foundation. Its local partner is the South African Tuberculosis Vaccine Initiative (Satvi), based at Cape Town University. Satvi is the largest dedicated TB vaccine research group in Africa.Currently there is only one TB vaccine available worldwide – the Bacille Calmette-Guérin or BCG vaccine, developed back in 1921. This is the drug administered to infants at birth. With TB evolving in recent years into drug-resistant and extensively drug-resistant strains, the almost century-old BCG is no longer as effective as it once was.According to Aeras, the BCG vaccine provides protection against severe forms of infant TB but cannot be relied upon for the adult form of the disease. Since TB is most prevalent in adults it is imperative that a vaccine be developed that is effective in combating all strains of TB, including drug-resistant versions. BCG is the most widely-administered vaccine in the world, says Aeras, but still the TB burden is increasing.According to Tony Hawkridge of Satvi, BCG is also dangerous for those suffering from Aids, and may also be unsafe for HIV-positive patients. This is because BCG is a live vaccine that may further compromise an already-weakened immune system.However, the new vaccine works alongside BCG and is intended to enhance the body’s immune response, which will have already been activated by the administration of BCG. It does this by using a protein from the pathogen, the Mycobacterium tuberculosis bacterium, to boost production of T-cells, a type of white blood cell that defends the body against infection.Collaborative effortAeras is also working with the Oxford-Emergent Tuberculosis Consortium in development of the new vaccine. This is a collaborative effort between researchers at Oxford University and US-based Emergent BioSolutions, a pharmaceutical company that specialises in the development of vaccines against killer diseases such as anthrax, botulism, tuberculosis, typhoid, and hepatitis B.The new vaccine, known as MVA85A/AERAS-485, was developed by Wellcome Trust senior research fellow Dr Helen McShane and her team at Oxford’s Jenner Institute. McShane commented that this is the first experimental TB vaccine to advance to phase II of a clinical trial in more than 80 years.“It’s the first of new-generation TB vaccines to go into this kind of study looking at efficacy in infants,” she said. “It’s enormously exciting, and I sincerely hope we will see some efficacy.”The cost of the study is estimated at US$14-million (R124-million) and will be carried by Aeras and the Wellcome Trust, a UK-based charity that funds biomedical research around the world. Previous trial phases have already been carried out South Africa and the Gambia, with promising results.The trial, which involves some 2 750 South African children, will be based at the Brewelskloof TB Hospital in Worcester, Western Cape. Researchers are currently in the process of selecting the participating infants. All children will already have received BCG at birth, as is the standard practice, and at 18 weeks half of them will get MVA85A while the other half will be given a placebo.According to McShane, the team is hoping for at least a 60% reduction in the incidence of pulmonary TB among children who receive the vaccine, compared with children who get the placebo. She added that initial results may be available as early as 2011 or 2012.“There is still a long road ahead,” remarked Aeras CEO Jerald Sadoff, “but this marks an important milestone toward the goal of a more effective TB vaccine.”“We believe this is the most exciting advance in the field of TB vaccines for over 80 years,” said McShane. “We have shown that this vaccine is safe and stimulates strong immune responses. This trial will hopefully show that the vaccine can protect people from getting TB and enable the global community to begin to control this devastating disease.”Global scourgeThe World Health Organisation (WHO) reports that about one third of the planet’s entire population is infected with TB. Despite the fact that TB is treatable and curable, of these roughly 2-billion people about 1.8-million succumb to the disease every year. A large number of them are children.TB is also a major killer of people with HIV and Aids, according to the WHO. There are about 33-million people living with HIV, of whom about a third are also infected with TB. Because their immune systems are weakened by the primary infection, around 90% of these people die within two to three months of contracting TB – unless they are treated.The incidence of TB is widespread in South Africa, and each year another 250 000 new cases are recorded in the country. According to Satvi, South Africa carries the seventh highest TB burden of all countries. Approximately 80 people die of the disease in South Africa every day, a figure that has been accelerated by the concurrent HIV epidemic.With 25% of all cases but only 10% of the population, the Western Cape is the hardest-hit by TB, which is one of the reasons the trial is taking place in that province.Between 15% and 20% of TB cases in South Africa are children. These young patients have contracted TB only recently, which demonstrates that current TB control measures are not doing what they should.Extensive testingNo medicine can be released for public consumption without undergoing extensive clinical trials, which are conducted on human subjects over a period of time. A clinical trial can only be started once sufficient preliminary information has been collected on the non-clinical properties of the medication or device, and permission has been obtained from the health authority in the country where it is to take place.There are several phases to a clinical trial, which can take years to complete.The pre-trial phase involves in vivo and in vitro testing to gather initial data on efficacy, toxicity and the body’s interaction with the drug. Only once all this data has been evaluated is the decision made on whether or not the product merits further testing.Phase 0 involves a trial with very small doses on just a few subjects to gather data on the interaction between the body and the drug or device.Phase I involves administration of the device or drug to a slightly larger group of patients. If the product is a drug, subjects are given a range of doses so that the most effective therapeutic dose can be established, although this is still a lesser dose than that which causes adverse effects in animals. Patients are typically healthy volunteers.Phase II extends phase one, with a bigger group of patients or volunteers. This is the make-or-break stage for a drug, as it often happens that during this period patients will show negative side effects, or the drug or device will not work as well as hoped.If, during the initial phases, a product proves itself to be effective and safe, it will pass into phase III, which is considered the definitive assessment phase of the safety and effectiveness of a drug or device. Subject groups of up to 3 000 are involved. This is usually the longest and most expensive phase of testing and having successfully proven itself, sometimes in more than one phase III trial, the drug or device is submitted for regulatory approval. Once approval has been obtained, the manufacturer may begin to market the product.Phase IV sees continuing monitoring of the product and ongoing technical support once the product is on the market.Do you have queries or comments about this article? Contact Janine Erasmus at [email protected] articlesSaving more lives from TB, fasterSA, US join to fight tuberculosisTB diagnosis breakthroughUseful linksAeras Global TB World Health Organisation – TBBill & Melinda Gates FoundationWellcome TrustOxford-Emergent Tuberculosis ConsortiumEmergent BioSolutionsOxford UniversityJenner Institute – OxfordThe International Clinical Trials Registry Platformlast_img read more